Regulatory strategy shaped by science and FDA review experience.
We support medical technology companies across U.S. FDA pathway strategy, evidence planning, submission preparation, and review response, from first concept through post-market compliance.
Deficiency response, biocompatibility strategy, chemical characterization and E&L: we've got you covered.
Who We Work With
Indian MedTech Companies
Indian manufacturers and startups seeking U.S. FDA clearance or approval, including 510(k), De Novo, and PMA, who need a regulatory partner with direct FDA experience.
International Companies
Global medical device companies, including U.S., European, and APAC manufacturers, seeking support with U.S. FDA submissions, testing strategy, and CRO coordination for India-based studies.
CROs & Testing Laboratories
Contract research organisations and testing labs in India seeking scientific protocol design, regulatory alignment review, and expert guidance on what FDA actually requires from their studies.
Startups & Deep-Tech Ventures
Early-stage medical technology companies, including those in deep-tech incubators and innovation programs, building their regulatory strategy from the ground up, often for the first time.
Principle 01
Define the right regulatory question before generating the evidence.
Principle 02
Match evidence to risk , not to convention or volume.
Principle 03
Anticipate the reviewer's lens at every stage of the program.
Principle 04
Present the case as a technical argument that withstands expert review.
Because FDA review is not just document review.
Tacticity helps companies define the right questions early, generate the right evidence, and present the case clearly.
The strength of a submission is determined by how clearly the evidence answers the relevant risk questions, not by its volume.